Cost was cited at the top barrier to prescribing nonsteroidal mineralocorticoid antagonists (57%), sodium-glucose cotransporter 2 inhibitors (74%), and glucagon-like peptide 1 receptor agonists (84%).

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...

The number of people living with heart failure (HF) worldwide more than doubled between 1990 and 2023, reaching an estimated ...

Esperion launched a nationwide awareness campaign for bumetanide nasal spray (Enbumyst), a short-term intranasal loop ...

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection. Invivyd plans to seek accelerated approval for VYD2311 based ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. Insurance Business cited the AJMC study as evidence for its central argument: a larger PBM rebate ...

Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...

Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps ...

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...

AJMC: Despite ATTR-CM being a progressive disease, 74% of patients reported no change in perception. Is that reassuring from ...

"We believe retatrutide is a biologic application," Eli Lilly’s CEO Dave Ricks, MBA, told analysts on the company's second-quarter earnings call in August. The outcome will shape how long retatrutide ...